HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on CG Oncology (NASDAQ:CGON) and maintained a price target of $75.
May 28, 2024 | 10:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on CG Oncology and maintained a price target of $75.
The reiteration of a Buy rating and the maintenance of a $75 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100